Live Chat ×
Skip to main content

iAMP21 Acute Lymphoblastic Leukemia, a High-Risk Disease

From the 2020 Joint Annual Meeting (June 29, 2020)
Presented by Christine Harrison, PhD FRCPath FMedSci
This presentation will define iAMP21 in pediatric acute lymphoblastic leukemia and will describe its clinical effects. The methods by which it can be diagnosed will be discussed. Some interesting cases with possible iAMP21 will be presented.

LEARNING OBJECTIVES
At the conclusion of this presentation, participants will be able to:

  1. Genetically classify all patients with acute lymphoblastic leukemia
  2. Accurately identify iAMP21-ALL
  3. Summarize the potential mechanisms giving rise to iAMP21-ALL

CE ACCREDITATION
This recorded presentation is P.A.C.E. ® accredited. The instruction level for this activity is Intermediate. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of Hematology/Cytogenetics/Molecular Biology will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

LEVEL OF INSTRUCTION
This intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.